<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Rx Times Pharmacy Magazine&#187; Rx Times</title>
	<atom:link href="http://www.rxtimes.com/author/admin/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.rxtimes.com</link>
	<description>Pharmacy news, jobs, continuing education, community and more.</description>
	<lastBuildDate>Mon, 09 Jan 2012 03:45:59 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>Novartis Consumer Health Inc. voluntarily recalls certain over-the-counter products</title>
		<link>http://www.rxtimes.com/novartis-consumer-health-inc-voluntarily-recalls-certain-over-the-counter-products/</link>
		<comments>http://www.rxtimes.com/novartis-consumer-health-inc-voluntarily-recalls-certain-over-the-counter-products/#comments</comments>
		<pubDate>Mon, 09 Jan 2012 03:44:42 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[FDA+Drugs+Regulatory]]></category>
		<category><![CDATA[Featured]]></category>
		<category><![CDATA[Bufferin®]]></category>
		<category><![CDATA[Excedrin®]]></category>
		<category><![CDATA[Gas-X Prevention®]]></category>
		<category><![CDATA[NoDoz®]]></category>
		<category><![CDATA[Novartis Consumer Health Inc.]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5687</guid>
		<description><![CDATA[Novartis Consumer Health Inc. (NCH) informed customers, that it is voluntarily recalling all lots of select bottle packaging configurations from retailers of Excedrin® and NoDoz® products with expiry dates of December 20, 2014 or earlier as well as Bufferin® and Gas-X Prevention® products with expiry dates of December 20, 2013 or earlier, in the United [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/novartis-consumer-health-inc-voluntarily-recalls-certain-over-the-counter-products/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Bristol-Myers Squibb to Acquire Inhibitex</title>
		<link>http://www.rxtimes.com/bristol-myers-squibb-to-acquire-inhibitex/</link>
		<comments>http://www.rxtimes.com/bristol-myers-squibb-to-acquire-inhibitex/#comments</comments>
		<pubDate>Sun, 08 Jan 2012 03:28:36 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Business+Technology]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[Inhibitex]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5682</guid>
		<description><![CDATA[Bristol-Myers Squibb Company (NYSE:BMY) and Inhibitex, Inc. (Nasdaq:INHX) announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger. The transaction, with an aggregate purchase price of approximately $2.5 billion, has been approved [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/bristol-myers-squibb-to-acquire-inhibitex/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pfizer Completes Acquisition of Excaliard</title>
		<link>http://www.rxtimes.com/pfizer-completes-acquisition-of-excaliard/</link>
		<comments>http://www.rxtimes.com/pfizer-completes-acquisition-of-excaliard/#comments</comments>
		<pubDate>Fri, 02 Dec 2011 23:37:23 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Business+Technology]]></category>
		<category><![CDATA[Acquisition]]></category>
		<category><![CDATA[Excaliard]]></category>
		<category><![CDATA[Excaliard Pharmaceuticals]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[Pfizer]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5657</guid>
		<description><![CDATA[Pfizer Inc. (NYSE: PFE) announced today that it has completed its acquisition of Excaliard Pharmaceuticals, Inc., a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. “It is imperative at Pfizer that we continue to develop new and innovative treatments to address [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/pfizer-completes-acquisition-of-excaliard/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Eli Lilly and Company Named a Top Global Company for Leaders</title>
		<link>http://www.rxtimes.com/eli-lilly-and-company-named-a-top-global-company-for-leaders/</link>
		<comments>http://www.rxtimes.com/eli-lilly-and-company-named-a-top-global-company-for-leaders/#comments</comments>
		<pubDate>Thu, 01 Dec 2011 23:34:36 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Business+Technology]]></category>
		<category><![CDATA[Eli Lilly and Company]]></category>
		<category><![CDATA[top 25 global companies for leaders]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5655</guid>
		<description><![CDATA[Eli Lilly and Company (NYSE: LLY) has been named one of the top 25 global companies for leaders by Aon Hewitt in partnership with FORTUNE and the RBL Group. Lilly ranked 16th on the Global 25 list and 12th on the North American list. The survey is one of the most comprehensive studies of talent [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/eli-lilly-and-company-named-a-top-global-company-for-leaders/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Lilly Announces First and Only International, Prospective Observational Study Designed to Understand Barriers to Progression of Insulin Treatment</title>
		<link>http://www.rxtimes.com/lilly-announces-first-and-only-international-prospective-observational-study-designed-to-understand-barriers-to-progression-of-insulin-treatment/</link>
		<comments>http://www.rxtimes.com/lilly-announces-first-and-only-international-prospective-observational-study-designed-to-understand-barriers-to-progression-of-insulin-treatment/#comments</comments>
		<pubDate>Thu, 01 Dec 2011 23:32:07 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[FDA+Drugs+Regulatory]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[Eli Lilly and Company]]></category>
		<category><![CDATA[insulin]]></category>
		<category><![CDATA[MOSA1c]]></category>
		<category><![CDATA[Type 2 Diabetes]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5653</guid>
		<description><![CDATA[Eli Lilly and Company (NYSE: LLY) today announced it is conducting the first major international, prospective observational study designed to understand the real-world obstacles that people with type 2 diabetes face that prevent them from reaching their ultimate treatment goals. Many people with diabetes who take daily insulin resist a progression of insulin therapy that [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/lilly-announces-first-and-only-international-prospective-observational-study-designed-to-understand-barriers-to-progression-of-insulin-treatment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Provides Clearance for New Test to Detect Vitamin D Levels</title>
		<link>http://www.rxtimes.com/fda-provides-clearance-for-new-test-to-detect-vitamin-d-levels/</link>
		<comments>http://www.rxtimes.com/fda-provides-clearance-for-new-test-to-detect-vitamin-d-levels/#comments</comments>
		<pubDate>Wed, 30 Nov 2011 23:19:08 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[FDA+Drugs+Regulatory]]></category>
		<category><![CDATA[Abbott]]></category>
		<category><![CDATA[Vitamin D]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5649</guid>
		<description><![CDATA[Abbott (NYSE: ABT) announced today it has received clearance from the U.S. Food and Drug Administration for a fully-automated 25-OH Vitamin D assay performed on its widely used ARCHITECT®laboratory testing platform. Published data from the Third National Health and Nutrition Survey, reported in the Archives of Internal Medicine, show that less than a quarter of [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/fda-provides-clearance-for-new-test-to-detect-vitamin-d-levels/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Accepts ELIQUIS® (apixaban) New Drug Application</title>
		<link>http://www.rxtimes.com/fda-accepts-eliquis%c2%ae-apixaban-new-drug-application-for-review-for-the-prevention-of-stroke-and-systemic-embolism-in-patients-with-atrial-fibrillation/</link>
		<comments>http://www.rxtimes.com/fda-accepts-eliquis%c2%ae-apixaban-new-drug-application-for-review-for-the-prevention-of-stroke-and-systemic-embolism-in-patients-with-atrial-fibrillation/#comments</comments>
		<pubDate>Tue, 29 Nov 2011 23:16:31 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[FDA+Drugs+Regulatory]]></category>
		<category><![CDATA[apixaban]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[ELIQUIS®]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Pfizer]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5646</guid>
		<description><![CDATA[Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for ELIQUIS® (apixaban), an investigational compound for the prevention of stroke and systemic embolism in patients with atrial fibrillation. The FDA accepted the filing and assigned [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/fda-accepts-eliquis%c2%ae-apixaban-new-drug-application-for-review-for-the-prevention-of-stroke-and-systemic-embolism-in-patients-with-atrial-fibrillation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Abbott Expands Agreement with GSK for an Additional Investigational Cancer Immunotherapy Antigen</title>
		<link>http://www.rxtimes.com/abbott-expands-agreement-with-gsk-for-an-additional-investigational-cancer-immunotherapy-antigen/</link>
		<comments>http://www.rxtimes.com/abbott-expands-agreement-with-gsk-for-an-additional-investigational-cancer-immunotherapy-antigen/#comments</comments>
		<pubDate>Mon, 28 Nov 2011 23:13:18 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[FDA+Drugs+Regulatory]]></category>
		<category><![CDATA[Abbott]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[GSK]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5644</guid>
		<description><![CDATA[Abbott (NYSE: ABT) announced today that it will expand its existing agreement with GlaxoSmithKline Biologicals S.A. (GSK) to include the development of an additional companion diagnostic test in support of GSK&#8217;s cancer immunotherapy research program. Companion diagnostic tests are designed to identify specific DNA sequences to help guide physicians in determining which patients are more [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/abbott-expands-agreement-with-gsk-for-an-additional-investigational-cancer-immunotherapy-antigen/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pfizer to Acquire Excaliard Pharmaceuticals</title>
		<link>http://www.rxtimes.com/pfizer-to-acquire-excaliard-pharmaceuticals/</link>
		<comments>http://www.rxtimes.com/pfizer-to-acquire-excaliard-pharmaceuticals/#comments</comments>
		<pubDate>Tue, 22 Nov 2011 13:20:12 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Business+Technology]]></category>
		<category><![CDATA[Excaliard Pharmaceuticals]]></category>
		<category><![CDATA[Pfizer]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5572</guid>
		<description><![CDATA[Pfizer Inc. (NYSE: PFE) and Excaliard Pharmaceuticals, Inc. announced today that they have entered into a definitive agreement under which Pfizer will acquire Excaliard, a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. The acquisition is expected to close before the [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/pfizer-to-acquire-excaliard-pharmaceuticals/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>First FDA-Approved Supplemental Blood Test for Chagas Disease</title>
		<link>http://www.rxtimes.com/first-fda-approved-supplemental-blood-test-for-chagas-disease/</link>
		<comments>http://www.rxtimes.com/first-fda-approved-supplemental-blood-test-for-chagas-disease/#comments</comments>
		<pubDate>Tue, 22 Nov 2011 05:06:57 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[FDA+Drugs+Regulatory]]></category>
		<category><![CDATA[Abbott]]></category>
		<category><![CDATA[CDC]]></category>
		<category><![CDATA[Centers for Disease Control and Prevention]]></category>
		<category><![CDATA[Chagas Disease]]></category>
		<category><![CDATA[FDA]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5569</guid>
		<description><![CDATA[Abbott (NYSE: ABT) received approval from the U.S. Food and Drug Administration (FDA) for a new Chagas in vitro diagnostic test. The ABBOTT ESA Chagas is the first FDA-approved supplemental test that detects antibodies to Trypanosoma cruzi (T. cruzi), a parasite found only in the Americas and commonly acquired through contact with the blood-sucking triatomine, [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/first-fda-approved-supplemental-blood-test-for-chagas-disease/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

